Oxysterol Platform (Fibrosis)
Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases
PreclinicalActive
Key Facts
Indication
Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases
Phase
Preclinical
Status
Active
Company
About MAX BioPharma
MAX BioPharma is a preclinical biotech leveraging its proprietary Oxysterol Therapeutics® platform to develop small-molecule lipid drugs. Founded on discoveries from UCLA, the company's most advanced candidate, Oxy210, is an oral, antifibrotic/anti-inflammatory agent being developed for MASH. As a private, preclinical-stage company, MAX BioPharma is targeting large, unmet medical needs across fibrosis, inflammation, and infection, but faces the inherent risks of early-stage drug development and platform validation.
View full company profile